No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
bristol-myers squibb
ZymoGenetics Acquisition Highlights Competitive Hepatitis C Treatment Race
Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
FDA Hopes to Keep Pharma Honest With “Bad Ad” Program
Last week, the FDA unveiled its “Bad Ad” program to encourage physicians to report questionable pharmaceutical sales pitches.
Burrill Report: Biotech Innovation Gets the Cash
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.
Special Report: Fighting the U.S. AIDS Epidemic
An estimated 1.2 million people in the U.S. have the HIV virus. OneMedPlace speaks with AIDS advocate Michael Manganiello about the scope of the epidemic, the possibility of a vaccine, and what needs to happen to make a national AIDS strategy a reality.
AstraZeneca’s Heart Drug Beats Plavix in Phase III Study
Blood-thinning drug Plavix racks up over $8 billion in annual sales, but the blockbuster medication may have some new competition.